131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids

Détails

ID Serval
serval:BIB_6906334FD651
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids
Périodique
Cancer Research
Auteur(s)
Langmuir  V. K., McGann  J. K., Buchegger  F., Sutherland  R. M.
ISSN
0008-5472 (Print)
Statut éditorial
Publié
Date de publication
06/1989
Volume
49
Numéro
12
Pages
3401-6
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun 15
Résumé
LS174T human colon adenocarcinoma multicell spheroids were used to study the radiobiological aspects of radioimmunotherapy. The spheroids were incubated in 131I-anticarcinoembryonic antigen (B7) at an antibody concentration of 0.5 microgram/ml and at 131I concentrations of 2.5 and 7.5 microCi/ml. After incubation times of 90 h, clonogenic cells per spheroid were reduced by 1400-fold and 23-fold at the high and low 131I concentrations, respectively. 131I Nonspecific antibody (PX63) resulted in 2- and 1.2-fold reductions. Spheroid diameter was not significantly affected by therapy but histological examination revealed that there had been a significant reduction in the cell density, particularly near the spheroid surface. Using a theoretical model to estimate radiation dose, a radiation survival curve was constructed. The resulting curve was somewhat concave suggesting the presence of a resistant population of cells. It is likely that this observation is primarily due to the fact that the inner cells received a lower dose than the outer cells. A population of radiobiologically hypoxic cells in the inner portion of the spheroids may also have contributed to the decreasing slope of the curve as well as ongoing cell division leading to new cells which receive a lower radiation dose per cell cycle. Because of the ability to estimate radiation dose for a given biological effect, these types of experiments may allow predictions of the efficacy of radiolabeled antibody therapy for micrometastatic disease.
Mots-clé
Adenocarcinoma/radiotherapy/*therapy Antibodies, Monoclonal/*therapeutic use Carcinoembryonic Antigen/*immunology Cell Line Colonic Neoplasms/radiotherapy/*therapy Dose-Response Relationship, Radiation Humans Iodine Radioisotopes/*therapeutic use Models, Biological Tumor Cells, Cultured/radiation effects Tumor Stem Cell Assay
Pubmed
Web of science
Création de la notice
25/01/2008 12:27
Dernière modification de la notice
20/08/2019 15:24
Données d'usage